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Abstract
Background: Lung fibrosis is a devastating pulmonary disorder characterized by alveolar epithelial injury,
extracellular matrix deposition and scar tissue formation. Due to its potent collagenolytic activity,
cathepsin K, a lysosomal cysteine protease is an interesting target molecule with therapeutic potential to
attenuate bleomycin-induced pulmonary f i b ro si s i n m i c e .  W e  he re  t e sted the hypothesis that over-
expression of cathepsin K in the lungs of mice is protective in bleomycin-induced pulmonary fibrosis.
Methods: Wild-type and cathepsin K overexpressing (cathepsin K transgenic; cath K tg) mice were
challenged intratracheally with bleomycin and sacrificed at 1, 2, 3 and 4 weeks post-treatment followed by
determination of lung fibrosis by estimating lung collagen content, lung histopathology, leukocytic
infiltrates and lung function. In addition, changes in cathepsin K protein levels in the lung were determined
by immunohistochemistry, real time RT-PCR and western blotting.
Results:  Cathepsin K protein levels were strongly increased in alveolar macrophages and lung
parenchymal tissue of mock-treated cathepsin K transgenic (cath K tg) mice relative to wild-type mice and
further increased particularly in cath K tg but also wild-type mice in response to bleomycin. Moreover,
cath K tg mice responded with a lower collagen deposition in their lungs, which was accompanied by a
significantly lower lung resistance (RL) compared to bleomycin-treated wild-type mice. In addition, cath K
tg mice responded with a lower degree of lung fibrosis than wild-type mice, a process that was found to
be independent of inflammatory leukocyte mobilization in response to bleomycin challenge.
Conclusion:  Over-expression of cathepsin K reduced lung collagen deposition and improved lung
function parameters in the lungs of transgenic mice, thereby providing at least partial protection against
bleomycin-induced lung fibrosis.
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Background
Lung fibrosis is an unrelenting pulmonary disease afflict-
ing more than 5 million patients worldwide [1]. Patients
diagnosed with pulmonary fibrosis have an average sur-
vival of < 2 yr from time of diagnosis [2,3]. The disease
process is characterized by alveolar epithelial cell injury
and hyperplasia, inflammatory cell accumulation, fibrob-
last hyperplasia, formation of honeycomb cysts and exu-
berant production and deposition of extracellular matrix
(ECM) components, particularly collagen and fibronectin
along with scar tissue formation [2,4]. Until now, anti-
inflammatory agents and immune modulators have
proved to be minimally effective in limiting alveolitis and
modifying the course of the disease, thus underlining the
urgent need for novel therapeutic intervention strategies.
Cathepsin K (Cath K) is a member of the lysosomal
cysteine and aspartic proteinase family, and has been
shown to possess unique collagenolytic activities [5].
Cathepsin K is expressed in bone osteclasts and chondro-
clasts, but also in epithelioid cells and multinucleated
giant cells in lung granulomatous lesions, whereas it is
largely absent in resident alveolar macrophages of the
lung under baseline conditions [6]. In addition, cath K
was observed in lung fibroblasts and bronchial epithe-
lium in normal adult lung tissue [6,7]. Recent reports
from our group showed that mice deficient of cathepsin K
responded with a significantly increased extracellular
matrix deposition to challenge with bleomycin when
compared to wild-type mice with a normal cath K expres-
sion, thus for the first time suggesting a protective role of
cathepsin K in lung matrix homeostasis under physiolog-
ical and pathological conditions [8]. Based on these
observations, we hypothesized that over-expression of
cathepsin K in the lungs of mice would ameliorate lung
fibrosis and lung resistance in mice challenged with bleo-
mycin. To test this hypothesis, cathepsin K transgenic
mice were challenged with bleomycin and their lung cell-
and tissue-specific cathepsin K expression, lung fibrosis,
and lung function was compared with that of bleomycin-
treated wild-type mice.
Methods
Animals
Cathepsin K transgenic (cath K tg) mice on a FVB/N back-
ground were generated as described recently [9]. For all
the experiments, we used homozygote siblings (cathepsin
K transgenic) derived from matings of heterozygous cath
K transgenic mice that were identified by genotyping
according to established real-time PCR protocols [10],
using genomic DNA extracts from tail snips of the respec-
tive mice. Corresponding genotyping results were further
confirmed by southern blot analysis (data not shown).
Experimental animals were 8–12 weeks old and were used
in accordance with the guidelines of our Institutional Ani-
mal Care and Use Committee. All experiments involving
animals were approved by our local government authori-
ties.
Reagents
Bleomycin was purchased from Medac (Hamburg, Ger-
many). Hydroxyproline was purchased from Sigma
(Deisenhofen, Germany). Mononclonal anti-cathepsin K
antibody was purchased from Calbiochem (via EMD Bio-
sciences, Darmstadt, Germany). Fetal calf serum (FCS)
and RPMI 1640 medium were purchased from PAA labo-
ratories (Pasching, Austria). Roti-Quick kit for total RNA
isolation was purchased from Carl Roth (Karlsruhe, Ger-
many). SYBR green 1 kit for real time RT-PCR was pur-
chased from Eurogentec (Seraing, Belgium). Collagenase
A was purchased from Roche (Mannheim, Germany).
DNase 1 was purchased from Serva (Heidelberg, Ger-
many). Random hexamer primers, MMLV-reverse tran-
scriptase, recombinant RNase inhibitor, dNTPs and DTT
were all purchased from Promega (Madison, US).
Bleomycin application
Intratracheal application of bleomycin in cath K tg and
wild-type mice was done essentially as described earlier
[8,11]. Briefly, tracheas of anaesthetized mice were surgi-
cally exposed and an Abbocath catheter (Abbott, Wies-
baden, Germany) was inserted into the trachea.
Subsequently, 0.025 U of bleomycin diluted in sterile
saline or saline only was slowly instilled under streomi-
croscopic control (Leica MS5, Wetzlar, Germany). After
instillations, the skin was sutured and mice were allowed
to recover with free access to food and water.
Collagen content measurements
Wild-type mice and cath K tg mice were either instilled
saline or 0.025 U of bleomycin and then euthanized at
various time points (1, 2, 3, and 4 weeks) post-treatment.
Subsequently, lungs were harvested and assayed for their
collagen content by hydroxyproline dye binding assays
according to published protocols [12], with some modifi-
cations. Briefly, for hydroxyproline measurements, lungs
were perfused with saline containing 0.1 M heparin until
the lung tissue appeared visually free of blood. While
avoiding contaminations with conducting airways and
lymphatic tissue, lung lobes were excised, cut into small
pieces and homogenized in sterile distilled water followed
by overnight hydrolysis in 6N hydrochloric acid at 110°C.
Next day, hydrolyzed samples were neutralized in 5N
NaOH and dried overnight using a speedvac set at 45°C.
For quantification of the collagen content, dried samples
were suspended in a small volume of sterile distilled water
and thoroughly vortexed followed by addition of assay
buffer and chloramine T-reagent. After a brief incubation,
DMBA reagent was added and samples were further incu-
bated for 20 min at 60°C. Total collagen content wasRespiratory Research 2008, 9:54 http://respiratory-research.com/content/9/1/54
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finally estimated by measuring the absorbance at 570 nm
against a reference wavelength of 650 nm and co-relating
them against a hydroxyproline standard.
Collection of bronchoalveolar lavage fluid (BALF)
Bronchoalveolar lavage fluid was collected from saline or
bleomycin-treated wild-type and cath K tg mice after 1, 2,
3 and 4 weeks post bleomycin instillation according to
recently published protocols [10,11,13-15]. Total cell
numbers recovered by BAL were counted with viabilities
as determined by trypan blue dye exclusion always
exceeding >90%. BAL fluid aliquots were cytospun onto
glass slides (Shandon, UK) and subjected to Pappenheim
staining for the differentiation and quantification of BAL
fluid cellular constituents. In separate experiments, to
investigate whether cathepsin K protein would also be
contained in BAL fluids of mice of the respective treat-
ment groups, BAL supernatants from wild-type mice or
cath K tg mice treated with bleomycin for two weeks were
collected and concentrated using VIVAspin 6 centrifugal
concentrators (Sartorius, Göttingen, Germany), and these
samples were used for the determination of extracellular
cathepsin K protein content by western blotting and gela-
tin zymography.
Isolation of primary type II alveolar epithelial cells
Primary type II alveolar epithelial cells (AEC) were iso-
lated from saline or bleomycin treated wild-type and cath
K tg mice after two weeks of bleomycin challenge accord-
ing to recently described protocols, with some modifica-
tions [16,17]. Briefly, mice were euthanized with an
overdose of isoflurane and exsanguinated by cutting the
inferior vena cava. Lungs were perfused gently with 10 ml
of sterile HBSS via the right ventricle until they were visu-
ally free of blood. A small incision was made into the
exposed trachea and a shortened 21-gauge cannula was
inserted and firmly fixed with a suture. Sterile dispase
(approx. 1 ml; BD Biosciences) followed by 500 μl of ster-
ile 1% low-melting agarose in PBS-/- (Sigma-Aldrich) was
gently instilled into the lungs. After a short incubation,
the lungs were removed and placed into a culture tube
containing 2 ml of dispase and incubated for 40 min at
room temperature. Lungs were then transferred into a cul-
ture dish containing DMEM/2,5% HEPES buffer/0.01%
DNase (Serva), and the tissue was carefully dissected from
the airways and large vessels. The resultant cell suspension
was successively filtered, re-suspended in 10 ml of DMEM
supplemented with 10% FCS and antibiotics, and incu-
bated with biotinylated rat anti-mouse CD16/32 and rat
anti-mouse CD45 mAbs (BD Pharmingen) for 30 min at
37°C. Cells were then washed and incubated with strepta-
vidin-conjugated MagneSphere Paramagnetic Particles
(Promega) for 30 min at room temperature with gentle
rocking, followed by magnetic removal of contaminating
leukocytes. Purities of freshly isolated AEC was always
>90%, as assessed by modified Papanicolaou staining spe-
cific for type II AEC. Viabilities of isolated AEC were
always >95%, as assessed by trypan blue dye exclusion.
Primary AEC were lysed either in Guanidine Isothiocy-
anate (GITC) or protein lysis buffer for subsequent real-
time RT-PCR or western blot analysis, respectively.
Preparation of lung homogenate
Lungs were perfused with HBSS supplemented with
heparin. Thereafter, removed lungs were cut into small
pieces and homogenized in 3 ml of protease inhibitor
cocktail. The resulting suspension was passed through
100 μM cell strainer and centrifuged. The resulting cell
pellet was washed with 1 ml of ice-cold PBS and centri-
fuged. The supernatant was discarded and 200 μl of lysis
buffer was added to the pellet and incubated over ice for
30 min with intermittent mixing. After incubation, the
lysate was centrifuged again at 13,000 rpm for 30 min and
the supernatant containing the protein was stored at -
80°C until western blot analysis was performed.
Total cellular RNA isolation, cDNA synthesis and real-time 
RT-PCR
Total cellular RNA was isolated from BAL cells, freshly iso-
lated alveolar type-II epithelial cells and lung homoge-
nates of saline or bleomycin treated wild-type and cath K
tg mice after two weeks of bleomycin challenge using a
commercially available RNA isolation kit (Carl Roth), fol-
lowing the instructions of the manufacturer. RNA quanti-
fication and purity was determined on an Agilent
Bioanalyzer 2100 (Agilent Biosystems) and only those
RNA preparations exceeding absorbance ratios of (A260/
280) > 1.90 were further processed for reverse transcription
and real-time RT-PCR analysis, as described recently [10].
For normalization, β-actin was used as the housekeeping
gene and mean fold-changes were calculated using the 2-
ΔΔCTCT method [18]. Primer sequences for PCR detection
of cathepsin K mRNA levels are forward 5'-gggccaggat-
gaaagttgta-3', and reverse 5'-cactgctctcttcagggctt-3' [19].
Western blotting
For cell-specific detection of cathepsin K protein in BAL
cells, lung homogenates and type II alveolar epithelial
cells from wild-type or cath K tg mice, cell lysates were pre-
pared in 100 μl of ice cold lysis buffer and equal amounts
of protein (20 μg each) were loaded onto 12.5% SDS-
polyacrylamide gels and electrophoretically transferred to
PVDF membranes (Roth, Karlsruhe, Germany). Cath K
protein was detected with anti-cathepsin K monoclonal
Ab detecting the mature form of cathepsin K (molecular
weight, 29 kDa) (Calbiochem, Darmstadt, Germany)
using chemiluminescence ECL substrate (Amersham,
Buckinghamshire, UK). Stripped blots were re-probed
with anti-β-actin monoclonal Ab (clone AC-15, Sigma,
Munich, Germany).Respiratory Research 2008, 9:54 http://respiratory-research.com/content/9/1/54
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Lung histopathology and degree of lung fibrosis
Wild-type mice and cath K tg mice were either mock-
treated with saline or received 0.025 U of bleomycin and
were then euthanized at various time points (1, 2, 3 and 4
weeks) post bleomycin treatment. Subsequently, lungs
were inflated in situ with PBS-buffered formaldehyde solu-
tion (4.5%, pH 7.0, Roth, Darmstadt, Germany), and then
carefully removed and immersed in PBS-buffered formal-
dehyde solution for at least 24 h at room temperature.
Lung tissue samples were paraffin-embedded, and sec-
tions of 5 μm were prepared and stained with hematoxy-
lin/eosin (H/E) and Trichrome staining (Elastica-van-
Gieson). The degree of lung fibrosis was determined
according to the method described by Ashcroft and col-
leagues [20], employing a numerical scaling system in
lung samples ranging from 0 (normal lung) to 8 (total
fibrous obliteration of the field). The mean degree of lung
fibrosis according to the definitions by Ashcroft et al. [20]
was calculated from individual scores of ~15 microscopic
fields analyzed per mouse lung.
Zymography
BAL fluids were concentrated using a spin concentrator
(Vivaspin, Sartorius, Göttingen, Germany). Subsequently,
50 μg of total BAL fluid protein was mixed with sample
loading buffer (Roth, Deisenhofen, Germany) and
zymography was performed essentially as described previ-
ously [21] with some modifications. Briefly, protein sam-
ples were loaded on 12.5% SDS-polyacrylamid gel
containing 0.1% gelatin. After electrophoresis, gels were
washed twice in 2.5% Triton X-100, rinsed four times in
distilled water and incubated overnight in assay buffer
(0.1 M sodium acetate, pH 5.5, 1 mM EDTA, 2 mM DTT
[22]. Subsequently, gels were stained with colloidal
Coomassie (Roth) according to the manufacturer's
instructions to visualize protease activity.
Immunohistochemistry
Formalin-fixed lung specimen from sham-treated wild-
type mice and cath K tg mice were subjected to immuno-
histochemical analysis, as described recently in detail
[8,23]. Briefly, immunostaining was performed on lung
sections (5 μm) using monoclonal antibody directed
against mouse cathepsin K (dilution 1:50, Calbiochem,
Darmstadt, Germany). Biotin-conjugated anti-mouse IgG
(H+L), diluted 1:200 from MOM Kit (Vector Laboratories,
CA) was used as the secondary antibody. Immunoreac-
tions were visualized using the avidin biotin complex
method applying Vectastain ABC peroxidase or alkaline
phosphatase kits (Vector Laboratories). 3,3'-Diaminoben-
zidine was used as the substrate and sections were coun-
ter-stained with hemalaun. The specificity of
immunostaining was tested by substitution of primary
antibodies with irrelevant antibodies. Slides were exam-
ined at a × 40 original magnification using an inverted
microscope (Zeiss axiovert 200, Oberkochen, Germany)
equipped with a digital imaging unit.
Lung function measurements
For measurements of lung resistance and compliance,
wild-type mice and cath K tg mice pre-treated with bleo-
mycin for two weeks were anaesthetized with 1.5%
halothane/30% oxygen by inhalation soon after pre-med-
ication with 77 mg/kg propofol given by intraperitoneal
injection. At the time when anesthesia was achieved, mice
were carefully intubated oro-tracheally under visual con-
trol by trans-illumination of the neck. The technique for
invasive but repetitive lung function measurement used in
this study has been described recently [24,25]. Briefly, two
intubated, spontaneously breathing animals were placed
in supine position in temperature-controlled body
plethysmographs (type 871, HSE-Harvard Apparatus,
March-Hugstetten, Germany). The oro-tracheal tube was
directly attached to a pneumotachograph (HSE) con-
nected to a differential pressure transducer to determine
tidal flow. Trans-pulmonary pressure (PTP) was measured
via a water-filled esophagus catheter coupled to a pressure
transducer (P75, HSE). Lung resistance (RL) and dynamic
lung compliance (Cdyn) were calculated from PTP and
tidal flow and volume signals over an entire breath cycle.
After reaching steady state conditions, respiratory param-
eters were continuously recorded and averaged for 5 min
using HEM 3.5 software (Notocord, Croissy, France). After
measurements, mice were extubated as soon as they began
recovering from anesthesia and placed back into their
cages with free access to food and water.
Statistical analysis
All data are presented as mean ± SD. Statistical analysis for
all the experiments was done by Student t-test or ANOVA
followed by post hoc Dunnett test, where appropriate to
determine significant differences between groups. P val-
ues of < 0.05 were considered to indicate statistically sig-
nificant differences.
Results
Characterization of cathepsin K overexpression in the 
lungs of mice
We initially characterized cathepsin K overexpression in
the lungs of transgenic mice compared to wild-type mice.
Analysis of cathepsin K mRNA and protein levels in
lysates of resident alveolar macrophages and lung
homogenates revealed 9.3-fold and 6.4-fold upregulated
cathepsin K mRNA levels in alveolar macrophages and
lung homogenates, respectively of the transgenic mice as
compared to mock-treated wild-type mice (Figure 1A).
Also, baseline cathepsin K protein levels were strongly
increased in the respective samples collected from cath K
overexpressing mice when compared to wild-type mice
(Figure 1B, D). In contrast, freshly prepared, primary typeRespiratory Research 2008, 9:54 http://respiratory-research.com/content/9/1/54
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Characterization of cathepsin K overexpression in the lungs of mice Figure 1
Characterization of cathepsin K overexpression in the lungs of mice. Wild-type and cath K tg mice were instilled with 
saline only (mock-treatment). Twenty-four hours later, cathepsin K mRNA levels were determined in lysates of alveolar mac-
rophages and lung parenchymal tissue of mock-treated cath K tg mice as compared to mock-treated wild-type mice (A). In 
addition, cathepsin K protein was determined in lysates of alveolar macrophages (B), freshly isolated type II alveolar epithelial 
cells (C), lung parenchymal tissue (D), and concentrated BAL fluid supernatant (E) of mock-treated cath K transgenic and wild-
type mice by western blot analysis. Data represent at least 3–5 independent experiments. (F-I), immunohistochemistry of cath 
K protein in lung tissue of wild-type mice (F, H) or cath K tg mice (G, I). (F, G) staining with isotype-matched control antibody; 
(H, I) cathepsin K specific staining. Arrows point to alveolar macrophages in situ. Photogmicrographic illustration is representa-
tive of at least n = 3 independent analyses. Original magnification, × 40
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II alveolar epithelial cells of both wild-type and cath K tg
mice completely lacked cathepsin K protein (Figure 1C).
Interestingly, concentrated BAL supernatants of mice of
both experimental groups were found to contain cathep-
sin K protein, suggesting that under baseline conditions,
low levels of cathepsin K protein is also released into the
bronchoalveolar compartment (Figure 1E). In addition,
immunohistochemical analysis of lung sections collected
from sham-treated wild-type mice and cath K tg mice
revealed low cathepsin K immunoreactivity in alveolar
macrophages of wild-type mice and a strongly increased
immunoreactivity noted in alveolar macrophages of
cathepsin K overexpressing mice (Figure 1F–I).
Cathepsin K transgenic mice exhibit decreased collagen 
deposition in their lungs in response to bleomycin 
compared to wild-type mice
Quantitative measurement of collagen content in the
lungs of wild-type mice and cath K tg mice by hydroxypro-
line assay at various time points post bleomycin challenge
showed that transgenic mice exhibiting connatal over-
expression of cathepsin K protein in their lungs consist-
ently demonstrated lower total collagen contents in lung
parenchymal tissue extracts as compared to wild-type
mice with statistically significant differences observed at 2
and 4 weeks post-treatment (Figure 2).
Effect of bleomycin application on cathepsin K expression 
in the lungs of mice
Our initial results showed that bleomycin-treated cath K
tg mice had lower collagen contents in their lungs com-
pared to wild-type mice. Therefore, we questioned
whether this effect might be due to further bleomycin-
induced upregulation of cathepsin K protein in the trans-
genic mice as opposed to bleomycin-challenged wild-type
mice. Also, an increased bleomycin-triggered inflamma-
tory lung leukocyte recruitment carrying increased cathep-
sin K protein cargo into the lungs might additionally or
alternatively underly the lower collagen contents
observed in the transgenic mice. Thus, we determined
cathepsin K mRNA and protein levels and proteolytic
activity in mice of either treatment group at various time
points post-bleomycin. Bleomycin treatment resulted in a
significantly increased cath K transcription and protein
expression both in alveolar macrophages and lung tissue
homogenate of cath K tg mice compared to wild-type mice
(Figure 3A,B,D), demonstrating that transgene-dependent
increased cath K levels noted under baseline conditions
were further upregulated in response to bleomycin chal-
lenge. We also observed increased cathepsin K protein
contents and proteolytic activities in cell-free BAL fluid
concentrates prepared from the lungs of mock-treated and
bleomycin-treated cath K tg relative to wild-type mice
(Figure 3E, F). On the other hand, no cathepsin K protein
was detected in type II epithelial cell lysates of bleomycin-
challenged mice of either treatment group at two weeks
post-treatment (Figure 3C), confirming and expanding
recent reports from our group [8].
We next questioned whether differences in inflammatory
leukocyte recruitment between cath K tg mice and wild-
type mice contributed to differences in lung cathepsin K
protein profiles noted in the two experimental groups
challenged with bleomycin. However, numbers of alveo-
lar macrophages, exudate macrophages, neutrophils and
lymphocytes contained in BAL fluids of mice of either
treatment group did not reveal any statistically significant
differences between groups, as shown in Figure 4 A-E.
These data show that the observed differences in cathep-
sin K protein profiles were not due to differential inflam-
matory leukocyte recruitment between groups.
Bleomycin-induced histopathology in wild-type mice as 
compared to cathepsin K transgenic mice
Histopathological analysis of lung sections from mock-
treated wild-type mice or cathepsin K tg mice displayed a
similar lung architecture with no differences noted
between groups (data not shown). By one week post-ble-
omycin treatment, wild-type mice and cathepsin K trans-
Cathepsin K transgenic mice exhibit decreased collagen dep- osition in their lungs in response to bleomycin compared to  wild-type mice Figure 2
Cathepsin K transgenic mice exhibit decreased colla-
gen deposition in their lungs in response to bleomy-
cin compared to wild-type mice. Cathepsin K transgenic 
mice (black bars) and wild-type mice (white bars) were 
administered either saline or bleomycin for 1, 2, 3, and 4 
weeks. Subsequently, mice were euthanized and lungs were 
processed for quantitative assessment of collagen content by 
hydroxyproline assay, as described in Materials and Methods. 
The data are shown as mean ± SD of at least n = 10 mice per 
group and time point. * indicates p < 0.05 compared to wild-
type mice. + indicates significant increase (p < 0.05) com-
pared to mock-treated wild-type mice.
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Effect of bleomycin challenge on cathepsin K expression in the lungs of cath K transgenic and wild-type mice Figure 3
Effect of bleomycin challenge on cathepsin K expression in the lungs of cath K transgenic and wild-type mice. 
Cathepsin K transgenic mice (black bars) and wild-type mice (white bars) were treated with bleomycin for 14 days (A-E). Mice 
were then euthanized and BAL cells (A, B), freshly isolated type II alveolar epithelial cells (A, C), lung homogenate (A, D), and 
concentrated BAL fluid supernatant (E) were prepared for analysis of cath K mRNA by real-time RT-PCR (A) and western 
blotting (B-E). (A), data are given as fold change in cathepsin K mRNA of bleomycin-challenged cath K tg mice compared to 
wild-type mice. (F) Gelatin zymography employing concentrated BAL fluid protein from mock- or bleomycin-treated wild-type 
mice and cath K tg mice. Data are shown as mean ± SD of n = 3 determinations. (B-F), data represent at least n = 3–5 inde-
pendent analyses. * indicates p < 0.05 versus bleomycin-treated wild-type mice at day 14 post-treatment.
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Effect of bleomycin instillation on leukocyte subset recruitment into the lungs of mice. Figure 4
Effect of bleomycin instillation on leukocyte subset recruitment into the lungs of mice. Cathepsin K transgenic 
mice (black bars) and wild-type mice (white bars) were administered either saline or bleomycin for 1, 2, 3, and 4 weeks. Subse-
quently, mice were euthanized and lungs were lavaged as described in Materials and Methods. Total BAL fluid cell numbers (A), 
alveolar macrophages (B), exudate macrophages (C), neutrophils (D) and lymphocytes (E) were ascertained from Pappenheim-
stained cytospin preparations of BAL fluid. The data are shown as mean ± SD of at least n = 5 mice per group and time point. 
No statistical significances were noted between wild-type and Cathepsin K transgenic mice.
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Degree of lung fibrosis in wild-type mice and cathepsin K transgenic mice Figure 5
Degree of lung fibrosis in wild-type mice and cathepsin K transgenic mice. (A) Cathepsin K transgenic mice (black 
bars) and wild-type mice (white bars) were administered either saline or bleomycin for 1, 2, and 4 weeks. Subsequently, mice 
were euthanized and lungs were examined histopathologically as described in Materials and Methods and the degree of lung 
fibrosis per mouse lung was calculated according to the grading system described by Ashcroft et al. [20]. (B) Representative 
photomicrographs of Elastica van Gieson-stained lung tissue sections collected from wild-type mice and cath K tg mice at day 
28 post-bleomycin treatment. The data are shown as mean ± SD of at least n = 6 mice per group and time point. * indicates sig-
nificant increase (p < 0.05) compared to cathepsin K tg mice.
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genic mice were found to develop early perivascular and
peribronchial lymphohistiocytic infiltrates with signifi-
cantly increased lung fibrosis developing in the wild-type
but not cath K tg mice (Figure 5). At two and four weeks
post-treatment, both wild-type mice and cath K tg mice
demonstrated epithelial hyperplasia of terminal bronchi-
oles and surrounding alveoli and lymphohistiocytic infil-
tration of the alveolar septae with fibroblast proliferation.
Importantly, the degree of lung fibrosis according to the
socring system developed by Ashcroft et al. [20] was sig-
nificantly higher in wild-type mice relative to cath K tg
mice as early as one week post-bleomycin and even more
pronounced by four weeks post bleomycin challenge. Fig-
ure 5B shows representative trichrome (Elastica-van-Gie-
son)-stained lung tissue sections from mice of the
corresponding treatment groups, thereby illustrating the
differences in developing lung fibrosis between groups by
four weeks post-bleomycin challenge. These data demon-
strate that cathepsin K over-expression attenuates, at least
in part, lung histopathological manifestations developing
in response to bleomycin challenge (Figure 5).
Cathepsin K transgenic mice exhibit reduced lung 
resistance upon bleomycin challenge
Lung resistance (RL) and dynamic compliance (Cdyn) are
important end-points in the determination of pulmonary
mechanics [26]. Therefore, we determined lung resistance
and dynamic compliance in wild-type mice and cathepsin
K transgenic mice at 2 weeks post bleomycin application.
As shown in Figure 6, cathepsin K transgenic mice had a
similar lung resistance compared to wild-type mice under
baseline conditions (mock-treatment) (Figure 6A). How-
ever, in response to bleomycin challenge, lung resistance
significantly increased in the wild-type mice only but not
in the cath K transgenic mice, while at the same time,
dynamic compliance was significantly reduced in mice of
either treatment group challenged with bleomycin (Figure
6B).
Discussion
In the current study, we show that cathepsin K overex-
pressing mice were partially protected from bleomycin-
induced pulmonary fibrosis compared to wild-type mice
exhibiting a normal cathepsin K expression in their lungs,
as assessed by partially reduced lung collagen contents
and lack of increasing lung resistance in response to bleo-
mycin challenge. As such, the currently presented data add
to our recent report on the role of cathepsin K in contrib-
uting to collagen turnover in the lungs of mice.
Pulmonary fibrosis is a major clinical problem character-
ized by accumulation of extracellular matrix (ECM) pro-
teins, including collagen, fibronectin, proteoglycans, and
elastin, leading to abnormal lung architecture and severe
impairment of lung function [27]. There is currently no
therapy for pulmonary fibrosis or other fibrosing diseases,
leading to unacceptably high morbidity and mortality
rates among affected individuals [27,28]. Matrix metallo-
proteases (MMPs) have long been known to exert a myr-
iad of regulatory actions critical in tissue repair and
remodelling, including epithelial cell migration, prolifer-
ation, differentiation, and apoptosis, as well as release of
latent or bound growth factors from the ECM [29]. How-
ever, over the past few years, lysosomal proteases such as
Cathepsin K transgenic mice exhibit decreased lung resist- ance upon bleomycin challenge Figure 6
Cathepsin K transgenic mice exhibit decreased lung 
resistance upon bleomycin challenge. Cathepsin K 
transgenic mice (black bars) and wild-type mice (white bars) 
were treated with bleomycin for 14 days. Subsequently, mice 
were anaesthesized and their lung resistance (A) and dynamic 
compliance (B) were assessed and compared to controls (A, 
B). The data are shown as mean ± SD of at least n = 10 mice 
per group and time point. * indicates significant increase (p < 
0.05) compared to cathepsin K transgenic mice. + indicates 
significant decrease (p < 0.05) compared to the respective 
mock-treated mice.
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the cysteine protease cathepsin K have been linked with
matrix turnover and thus gained increasing attention
[30,31]. Cathepsin K is the most potent mammalian
elastase yet described, as it possesses a unique collageno-
lytic activity among other proteases [5,32]. Recent reports
from our group showed that cathepsin K plays a pivotal
role during bleomycin-induced lung fibrosis [8]. More
specifically, we found that cathepsin K knockout mice
(CTSK-/-) deposited significantly more extracellular matrix
upon bleomycin challenge than control mice, and pri-
mary lung fibroblasts derived from these animals showed
a decreased collagenolytic activity, thus supporting a role
for cathepsin K in lung collagen degradation. In the
present study, we found that global overexpression of
cathepsin K effected a partially increased extracellular
matrix turnover in the lungs of mice challenged with ble-
omycin. At the same time, an increased expression of
cathepsin K particularly in alveolar macrophages and lung
tissue homogenate but not in type II alveolar epithelial
cells both under baseline conditions and in response to
bleomycin was noted, suggesting that alveolar macro-
phages but not type II alveolar epithelial cells contributed,
at least in part, to the increased collagenolytic activities in
the transgenic as opposed to wild-type mice challenged
with bleomycin. In the current study, cathepsin K was not
detected in freshly isolated type II alveolar epithelial cells,
as opposed to bronchial epithelial cells previously
reported to express cathepsin K [7]. Thus, as opposed to
human or murine lung fibroblasts [8] or human bron-
chial epithelial cells [7], type II epithelial cells do not
appear to contribute to cathepsin K-dependent collageno-
lytic activities in bleomycin-induced lung fibrosis.
Since in the current study, numbers of BAL fluid cell dif-
ferentials were similar in the transgenic mice compared to
wild-type mice upon bleomycin treatment, the data sug-
gest that primarily the transgene-induced increased cathe-
psin K translation in alveolar macrophages rather than
differential leukocyte mobilization towards the lungs of
mice per se was responsible for the reduced collagen dep-
osition in the transgenic as compared to wild-type mice
challenged with bleomycin.
Lung resistance (RL) significantly increased in the wild-
type mice but not in the cath K overexpressing mice in
response to bleomycin challenge, whereas the classical
parameter to determine changes in lung elasticity due to
fibrosis, i.e. lung compliance [33], was not different
between groups. In the present study, lung resistance (RL)
was determined from the ratio of transpulmonary pres-
sure (PTP) to tidal flow over an entire breath cycle [25,26].
Of note, the parameter lung resistance includes airway
resistance but also lung tissue resistance. In normal
rodents, lung resistance nearly equals airway resistance
[33]. In restrictive airway diseases such as pulmonary
fibrosis, lung tissue resistance may become more impor-
tant and significantly contributes to RL and thus may have
contributed to the effects observed in the current study. In
addition, obstruction of peripheral airways also contrib-
utes to an increase in RL. Fibrosis is also thought to cause
airway obstruction mainly in peripheral airways, together
with the changes in structural rigidity of lung parenchy-
mal tissue due to lung interstitial inflammation and fibro-
sis resulting in decreased elastic recoil [24,25]. As such,
the currently presented data suggest that cathepsin K over-
expression in mice may at least partially prevent changes
in lung function evoked by bleomycin treatment.
One unresolved question of the current study is the iden-
tification of the mechanism by which bleomycin chal-
lenge further increased cathepsin K mRNA and protein
levels both in wild-type mice and in transgenic mice. A
more precise understanding of the factors governing
cathepsin K regulation in vivo would be particularly
important in view of future strategies to regulate its activ-
ity in fibrosing human lungs. Current experiments are
being performed to address this unresolved question.
Conclusion
Together, this study shows that overexpression of cathep-
sin K does not adversely affect normal lung architecture in
mice but at least partially protects against peak lung
fibrotic responses and lung resistance upon bleomycin
challenge. These data suggest a protective role of increased
cathepsin K levels to antagonize excessive ECM deposition
in diseased lungs.
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